loratadine and ketoconazole

loratadine has been researched along with ketoconazole in 26 studies

Research

Studies (26)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (3.85)	18.2507
2000's	15 (57.69)	29.6817
2010's	9 (34.62)	24.3611
2020's	1 (3.85)	2.80

Authors

Authors	Studies
Huang, L; Humphreys, JE; Morgan, JB; Polli, JW; Serabjit-Singh, CS; Webster, LO; Wring, SA	1
Keserü, GM	1
Nagashima, R; Nishikawa, T; Tobita, M	1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL	1
Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J	1
Jia, L; Sun, H	1
Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM	1
Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM	1
Austin, CP; Fidock, DA; Hayton, K; Huang, R; Inglese, J; Jiang, H; Johnson, RL; Su, XZ; Wellems, TE; Wichterman, J; Yuan, J	1
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM	1
Glen, RC; Lowe, R; Mitchell, JB	1
Sen, S; Sinha, N	1
Freiwald, S; Jiang, Y; Jones, JP; Kaspera, R; Katayama, J; Lee, CA; Smith, E; Totah, RA; Walker, GS	1
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR	1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ	1
Artursson, P; Mateus, A; Matsson, P	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Cayen, MN; Chen, KJ; Clement, RP; Huie, K; Snow, M; Yumibe, N	1
Affrime, MB; Batra, VK; Cayen, MN; Kosoglou, T; Lim, JM; Salfi, M	1
Affrime, M; Banfield, C; Herron, J; Keung, A; Padhi, D	1
Chaikin, P; Gillen, MS; Malik, M; Pentikis, H; Rhodes, GR; Roberts, DJ	1
de Lago, A; Gómez Silva, M; Gonzàlez-de la Parra, M; Lujàn Rangel, R; Namur, S; Pineyro-Garza, E; Piñeyro-López, A; Reyes-Araiza, R; Torres-Alanís, O; Trejo, D; Wacksman, N	1
Alton, KB; Alvarez, N; Chowdhury, SK; Ghosal, A; Gupta, S; Lu, X; Ramanathan, R; Su, AD; Yuan, Y; Zbaida, S	1
Kulig, M; Lisowski, B; Polak, S; Wiśniowska, B	1
Ahemad, N; Dong, AN; Ong, CE; Palanisamy, UD; Pan, Y; Yiap, BC	1
Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL	1

Reviews

1 review(s) available for loratadine and ketoconazole

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016

Trials

4 trial(s) available for loratadine and ketoconazole

Article	Year
Evaluation of the pharmacokinetics and electrocardiographic pharmacodynamics of loratadine with concomitant administration of ketoconazole or cimetidine. British journal of clinical pharmacology, 2000, Volume: 50, Issue:6 Topics: Adult; Antifungal Agents; Cimetidine; Consumer Product Safety; Cross-Over Studies; Drug Interactions; Electrocardiography; Histamine H1 Antagonists; Histamine H2 Antagonists; Humans; Ketoconazole; Loratadine; Male; Single-Blind Method	2000
Desloratadine has no clinically relevant electrocardiographic or pharmacodynamic interactions with ketoconazole. Clinical pharmacokinetics, 2002, Volume: 41 Suppl 1 Topics: Adult; Analysis of Variance; Antifungal Agents; Area Under Curve; Cross-Over Studies; Drug Interactions; Electrocardiography; Female; Histamine H1 Antagonists; Humans; Ketoconazole; Loratadine; Male; Middle Aged	2002
Co-administration of ketoconazole with H1-antagonists ebastine and loratadine in healthy subjects: pharmacokinetic and pharmacodynamic effects. British journal of clinical pharmacology, 2005, Volume: 59, Issue:3 Topics: Adolescent; Adult; Antifungal Agents; Butyrophenones; Double-Blind Method; Drug Combinations; Electrocardiography; Heart Rate; Histamine H1 Antagonists; Humans; Ketoconazole; Loratadine; Male; Piperidines	2005
Bioavailability of two oral formulations of loratadine 20 mg with concomitant ketoconazole: an open-label, randomized, two-period crossover comparison in healthy Mexican adult volunteers. Clinical therapeutics, 2006, Volume: 28, Issue:1 Topics: Administration, Oral; Adolescent; Adult; Antifungal Agents; Biological Availability; Cross-Over Studies; Drug Interactions; Drug Therapy, Combination; Follow-Up Studies; Histamine H1 Antagonists, Non-Sedating; Humans; Hypersensitivity; Ketoconazole; Loratadine; Male; Mexico; Middle Aged; Reference Values	2006

Other Studies

21 other study(ies) available for loratadine and ketoconazole

Article	Year
Rational use of in vitro P-glycoprotein assays in drug discovery. The Journal of pharmacology and experimental therapeutics, 2001, Volume: 299, Issue:2 Topics: Adenosine Triphosphatases; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cells, Cultured; Chromatography, Liquid; Enzyme Inhibitors; Fluoresceins; Fluorescent Dyes; Humans; Mass Spectrometry; Pharmacology; Spodoptera	2001
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods. Bioorganic & medicinal chemistry letters, 2003, Aug-18, Volume: 13, Issue:16 Topics: Cation Transport Proteins; Databases, Factual; Discriminant Analysis; Ether-A-Go-Go Potassium Channels; Holography; Linear Models; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship	2003
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors. Bioorganic & medicinal chemistry letters, 2005, Jun-02, Volume: 15, Issue:11 Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated	2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Current drug discovery technologies, 2004, Volume: 1, Issue:4 Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration	2004
Chemical genetics reveals a complex functional ground state of neural stem cells. Nature chemical biology, 2007, Volume: 3, Issue:5 Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells	2007
Support vector machines classification of hERG liabilities based on atom types. Bioorganic & medicinal chemistry, 2008, Jun-01, Volume: 16, Issue:11 Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve	2008
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2). Journal of medicinal chemistry, 2008, Jun-12, Volume: 51, Issue:11 Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship	2008
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1. Journal of medicinal chemistry, 2008, Oct-09, Volume: 51, Issue:19 Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship	2008
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum. Nature chemical biology, 2009, Volume: 5, Issue:10 Topics: Animals; Antimalarials; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromosome Mapping; Crosses, Genetic; Dihydroergotamine; Drug Design; Drug Resistance; Humans; Inhibitory Concentration 50; Mutation; Plasmodium falciparum; Quantitative Trait Loci; Transfection	2009
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models. Toxicology mechanisms and methods, 2008, Volume: 18, Issue:2-3 Topics:	2008
Predicting phospholipidosis using machine learning. Molecular pharmaceutics, 2010, Oct-04, Volume: 7, Issue:5 Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine	2010
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model. European journal of medicinal chemistry, 2011, Volume: 46, Issue:2 Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship	2011
Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity. Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:5 Topics: Amiodarone; Astemizole; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2J2; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Danazol; Drug Discovery; Drug Interactions; Enzyme Inhibitors; Humans; Hydroxylation; In Vitro Techniques; Methylation; Microsomes, Liver; Models, Biological; Molecular Structure; Substrate Specificity; Tandem Mass Spectrometry; Terfenadine	2012
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. Journal of medicinal chemistry, 2012, May-24, Volume: 55, Issue:10 Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection	2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests	2013
A high-throughput cell-based method to predict the unbound drug fraction in the brain. Journal of medicinal chemistry, 2014, Apr-10, Volume: 57, Issue:7 Topics: Animals; Brain; Dialysis; HEK293 Cells; High-Throughput Screening Assays; Humans; Pharmaceutical Preparations; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization	2014
Identification of human liver cytochrome P450 enzymes that metabolize the nonsedating antihistamine loratadine. Formation of descarboethoxyloratadine by CYP3A4 and CYP2D6. Biochemical pharmacology, 1996, Jan-26, Volume: 51, Issue:2 Topics: Anti-Bacterial Agents; Antifungal Agents; Antimalarials; Binding Sites; Biotransformation; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Histamine H1 Antagonists; Humans; In Vitro Techniques; Ketoconazole; Loratadine; Microsomes, Liver; Mixed Function Oxygenases; Models, Molecular; Oxidation-Reduction; Piperidines; Pyridines; Quinidine; Recombinant Proteins; Substrate Specificity; Troleandomycin	1996
Metabolism of loratadine and further characterization of its in vitro metabolites. Drug metabolism letters, 2009, Volume: 3, Issue:3 Topics: Administration, Oral; Biotransformation; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Histamine H1 Antagonists, Non-Sedating; Humans; Hydroxylation; Isoenzymes; Ketoconazole; Liver; Loratadine; Microsomes, Liver; Recombinant Proteins; Tablets; Tandem Mass Spectrometry	2009
Drug interaction at hERG channel: In vitro assessment of the electrophysiological consequences of drug combinations and comparison against theoretical models. Journal of applied toxicology : JAT, 2018, Volume: 38, Issue:4 Topics: Arrhythmias, Cardiac; Drug Combinations; Drug Interactions; Electrophysiology; ERG1 Potassium Channel; HEK293 Cells; Humans; In Vitro Techniques; Ketoconazole; Loratadine; Models, Theoretical; Patch-Clamp Techniques	2018
The Molecular and Enzyme Kinetic Basis for Altered Activity of Three Cytochrome P450 2C19 Variants Found in the Chinese Population. Current molecular pharmacology, 2020, Volume: 13, Issue:3 Topics: Alleles; Amino Acid Sequence; Asian People; Catalytic Domain; Coumarins; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inhibitors; Fluoxetine; Humans; Ketoconazole; Kinetics; Loratadine; Models, Molecular; Molecular Docking Simulation; Mutagenesis, Site-Directed; Nitriles; Omeprazole; Polymorphism, Genetic; Protein Conformation; Protein Isoforms; Recombinant Proteins; Sertraline; Substrate Specificity	2020
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics. PloS one, 2016, Volume: 11, Issue:10 Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat	2016